This HTML5 document contains 235 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n20http://linked.opendata.cz/resource/drugbank/drug/DB01060/identifier/chebi/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/AHFS/
n12http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n29http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01060/identifier/wikipedia/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01060/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/drugbank/dosage/
n22http://linked.opendata.cz/resource/drugbank/mixture/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01060/identifier/kegg-compound/
n27http://www.drugs.com/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01060/identifier/pubchem-compound/
n26http://bio2rdf.org/drugbank:
n25http://linked.opendata.cz/resource/drugbank/drug/DB01060/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n24http://www.rxlist.com/cgi/generic/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01060/identifier/drugbank/
n31http://linked.opendata.cz/resource/drugbank/patent/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/drug/DB01060/identifier/national-drug-code-directory/
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n28http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB01060/identifier/chemspider/
n30http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01060
rdf:type
n3:Drug
n3:description
A broad-spectrum semisynthetic antibiotic similar to ampicillin except that its resistance to gastric acid permits higher serum levels with oral administration. Amoxicillin is commonly prescribed with clauvanic acid (a beta lactamase inhibitor) as it is susceptible to beta-lacatamase degradation. [PubChem]
n3:dosage
n6:271B5CED-363D-11E5-9242-09173F13E4C5 n6:271B5CEE-363D-11E5-9242-09173F13E4C5 n6:271B5CEF-363D-11E5-9242-09173F13E4C5 n6:271B5CF0-363D-11E5-9242-09173F13E4C5 n6:271B5CF1-363D-11E5-9242-09173F13E4C5 n6:271B5CE5-363D-11E5-9242-09173F13E4C5 n6:271B5CE6-363D-11E5-9242-09173F13E4C5 n6:271B5CE7-363D-11E5-9242-09173F13E4C5 n6:271B5CE8-363D-11E5-9242-09173F13E4C5 n6:271B5CE9-363D-11E5-9242-09173F13E4C5 n6:271B5CEA-363D-11E5-9242-09173F13E4C5 n6:271B5CEB-363D-11E5-9242-09173F13E4C5 n6:271B5CEC-363D-11E5-9242-09173F13E4C5 n6:271B5CDD-363D-11E5-9242-09173F13E4C5 n6:271B5CDE-363D-11E5-9242-09173F13E4C5 n6:271B5CDF-363D-11E5-9242-09173F13E4C5 n6:271B5CE0-363D-11E5-9242-09173F13E4C5 n6:271B5CE1-363D-11E5-9242-09173F13E4C5 n6:271B5CE2-363D-11E5-9242-09173F13E4C5 n6:271B5CE3-363D-11E5-9242-09173F13E4C5 n6:271B5CE4-363D-11E5-9242-09173F13E4C5 n6:271B5CDA-363D-11E5-9242-09173F13E4C5 n6:271B5CDB-363D-11E5-9242-09173F13E4C5 n6:271B5CDC-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Drawz SM, Bonomo RA: Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010 Jan;23(1):160-201. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20065329
n3:group
approved
n3:halfLife
61.3 minutes
n3:indication
For the treatment of infections of the ear, nose, and throat, the genitourinary tract, the skin and skin structure, and the lower respiratory tract due to susceptible (only b-lactamase-negative) strains of <i>Streptococcus</i> spp. (a- and b-hemolytic strains only), <i>S. pneumoniae</i>, <i>Staphylococcus</i> spp., <i>H. influenzae</i>, <i>E. coli</i>, <i>P. mirabilis</i>, or <i>E. faecalis</i>. Also for the treatment of acute, uncomplicated gonorrhea (ano-genital and urethral infections) due to <i>N. gonorrhoeae</i> (males and females).
owl:sameAs
n11:DB01060 n26:DB01060
dcterms:title
Amoxicillin
adms:identifier
n8:Amoxicillin n15:PA448406 n16:33613 n17:C06827 n18:0781-6039-58 n19:DB01060 n20:2676 n21:31006 n25:46507578
n3:mechanismOfAction
Amoxicillin binds to penicillin-binding protein 1A (PBP-1A) located inside the bacterial cell well. Penicillins acylate the penicillin-sensitive transpeptidase C-terminal domain by opening the lactam ring. This inactivation of the enzyme prevents the formation of a cross-link of two linear peptidoglycan strands, inhibiting the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that amoxicllin interferes with an autolysin inhibitor.
n3:packager
n12:271B5C67-363D-11E5-9242-09173F13E4C5 n12:271B5C68-363D-11E5-9242-09173F13E4C5 n12:271B5C65-363D-11E5-9242-09173F13E4C5 n12:271B5C66-363D-11E5-9242-09173F13E4C5 n12:271B5C6B-363D-11E5-9242-09173F13E4C5 n12:271B5C7A-363D-11E5-9242-09173F13E4C5 n12:271B5C69-363D-11E5-9242-09173F13E4C5 n12:271B5C6A-363D-11E5-9242-09173F13E4C5 n12:271B5C7B-363D-11E5-9242-09173F13E4C5 n12:271B5C7C-363D-11E5-9242-09173F13E4C5 n12:271B5C84-363D-11E5-9242-09173F13E4C5 n12:271B5CA6-363D-11E5-9242-09173F13E4C5 n12:271B5C83-363D-11E5-9242-09173F13E4C5 n12:271B5CA9-363D-11E5-9242-09173F13E4C5 n12:271B5CAA-363D-11E5-9242-09173F13E4C5 n12:271B5CA7-363D-11E5-9242-09173F13E4C5 n12:271B5C74-363D-11E5-9242-09173F13E4C5 n12:271B5CA8-363D-11E5-9242-09173F13E4C5 n12:271B5C75-363D-11E5-9242-09173F13E4C5 n12:271B5CAD-363D-11E5-9242-09173F13E4C5 n12:271B5C72-363D-11E5-9242-09173F13E4C5 n12:271B5C73-363D-11E5-9242-09173F13E4C5 n12:271B5CAB-363D-11E5-9242-09173F13E4C5 n12:271B5C78-363D-11E5-9242-09173F13E4C5 n12:271B5CAC-363D-11E5-9242-09173F13E4C5 n12:271B5C79-363D-11E5-9242-09173F13E4C5 n12:271B5C76-363D-11E5-9242-09173F13E4C5 n12:271B5C77-363D-11E5-9242-09173F13E4C5 n12:271B5CA2-363D-11E5-9242-09173F13E4C5 n12:271B5CA3-363D-11E5-9242-09173F13E4C5 n12:271B5CA0-363D-11E5-9242-09173F13E4C5 n12:271B5CA1-363D-11E5-9242-09173F13E4C5 n12:271B5CA4-363D-11E5-9242-09173F13E4C5 n12:271B5CA5-363D-11E5-9242-09173F13E4C5 n12:271B5C7D-363D-11E5-9242-09173F13E4C5 n12:271B5C6C-363D-11E5-9242-09173F13E4C5 n12:271B5C7E-363D-11E5-9242-09173F13E4C5 n12:271B5C6D-363D-11E5-9242-09173F13E4C5 n12:271B5C81-363D-11E5-9242-09173F13E4C5 n12:271B5C82-363D-11E5-9242-09173F13E4C5 n12:271B5C70-363D-11E5-9242-09173F13E4C5 n12:271B5C71-363D-11E5-9242-09173F13E4C5 n12:271B5C7F-363D-11E5-9242-09173F13E4C5 n12:271B5C6E-363D-11E5-9242-09173F13E4C5 n12:271B5C80-363D-11E5-9242-09173F13E4C5 n12:271B5C6F-363D-11E5-9242-09173F13E4C5 n12:271B5C97-363D-11E5-9242-09173F13E4C5 n12:271B5C98-363D-11E5-9242-09173F13E4C5 n12:271B5C95-363D-11E5-9242-09173F13E4C5 n12:271B5C96-363D-11E5-9242-09173F13E4C5 n12:271B5C9B-363D-11E5-9242-09173F13E4C5 n12:271B5C9C-363D-11E5-9242-09173F13E4C5 n12:271B5C99-363D-11E5-9242-09173F13E4C5 n12:271B5C9A-363D-11E5-9242-09173F13E4C5 n12:271B5C9F-363D-11E5-9242-09173F13E4C5 n12:271B5C9D-363D-11E5-9242-09173F13E4C5 n12:271B5C9E-363D-11E5-9242-09173F13E4C5 n12:271B5C87-363D-11E5-9242-09173F13E4C5 n12:271B5C88-363D-11E5-9242-09173F13E4C5 n12:271B5C85-363D-11E5-9242-09173F13E4C5 n12:271B5C86-363D-11E5-9242-09173F13E4C5 n12:271B5C8B-363D-11E5-9242-09173F13E4C5 n12:271B5C8C-363D-11E5-9242-09173F13E4C5 n12:271B5C89-363D-11E5-9242-09173F13E4C5 n12:271B5C8A-363D-11E5-9242-09173F13E4C5 n12:271B5C8F-363D-11E5-9242-09173F13E4C5 n12:271B5C90-363D-11E5-9242-09173F13E4C5 n12:271B5C8D-363D-11E5-9242-09173F13E4C5 n12:271B5C8E-363D-11E5-9242-09173F13E4C5 n12:271B5C93-363D-11E5-9242-09173F13E4C5 n12:271B5C94-363D-11E5-9242-09173F13E4C5 n12:271B5C91-363D-11E5-9242-09173F13E4C5 n12:271B5C92-363D-11E5-9242-09173F13E4C5
n3:patent
n31:6544555
n3:routeOfElimination
Most of the amoxicillin is excreted unchanged in the urine; its excretion can be delayed by concurrent administration of probenecid.
n3:synonym
Amoxicilline alpha-amino-P-Hydroxybenzylpenicillin Amoxicillin anhydrous Moxal Amoxycillin 6-(P-Hydroxy-alpha-aminophenylacetamido)penicillanic acid p-Hydroxyampicillin (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Amoxicilina Amopenixin AX 6-(p-hydroxy-α-aminophenylacetamido)penicillanic acid Amoxicillinum Amoxicillin Clamoxyl α-amino-p-hydroxybenzylpenicillin Amox Amolin AMPC
n3:toxicity
Serious toxicity is unlikely following large doses of amoxicillin. Acute ingestion of large doses of amoxicillin may cause nausea, vomiting, diarrhea and abdominal pain. Acute oliguric renal failure and hematuria may occur following large doses.
n13:hasAHFSCode
n14:08-12-16-08
n3:foodInteraction
Take without regard to meals.
n3:mixture
n22:271B5C64-363D-11E5-9242-09173F13E4C5 n22:271B5C62-363D-11E5-9242-09173F13E4C5 n22:271B5C63-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
In blood serum, amoxicillin is approximately 20% protein-bound
n3:salt
n3:synthesisReference
Joan Cabre, Jose Diago, Asuncion Esteve, Johannes Ludescher, "Production of a crystalline salt of amoxicillin." U.S. Patent US6103897, issued April, 1971.
n28:hasConcept
n29:M0001009
foaf:page
n24:amox.htm n27:amoxicillin.html
n3:IUPAC-Name
n4:271B5CF6-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5CFC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5CFB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5CF8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5CF9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5CFA-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5D0C-363D-11E5-9242-09173F13E4C5 n4:271B5CF4-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5D0E-363D-11E5-9242-09173F13E4C5 n4:271B5CF5-363D-11E5-9242-09173F13E4C5 n4:271B5CF2-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5CF3-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n30:J01CA04
n3:H-Bond-Acceptor-Count
n4:271B5D02-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5D03-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5CFD-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5CFE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5D00-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5CFF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5D01-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed after oral administration.
n3:affectedOrganism
Chlamydia psittaci Chlamydia pneumoniae Gram negative and gram positive bacteria Borrelia burgdorferi Enteric bacteria and other eubacteria Streptococcus pyogenes Salmonella typhi Streptococcus pneumoniae
n3:caco2-Permeability
n4:271B5D0F-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
26787-78-0
n3:category
n3:containedIn
n5:271B5CB1-363D-11E5-9242-09173F13E4C5 n5:271B5CD6-363D-11E5-9242-09173F13E4C5 n5:271B5CD7-363D-11E5-9242-09173F13E4C5 n5:271B5CD8-363D-11E5-9242-09173F13E4C5 n5:271B5CD9-363D-11E5-9242-09173F13E4C5 n5:271B5CCA-363D-11E5-9242-09173F13E4C5 n5:271B5CCB-363D-11E5-9242-09173F13E4C5 n5:271B5CC8-363D-11E5-9242-09173F13E4C5 n5:271B5CC9-363D-11E5-9242-09173F13E4C5 n5:271B5CB9-363D-11E5-9242-09173F13E4C5 n5:271B5CCE-363D-11E5-9242-09173F13E4C5 n5:271B5CBA-363D-11E5-9242-09173F13E4C5 n5:271B5CCF-363D-11E5-9242-09173F13E4C5 n5:271B5CCC-363D-11E5-9242-09173F13E4C5 n5:271B5CB8-363D-11E5-9242-09173F13E4C5 n5:271B5CCD-363D-11E5-9242-09173F13E4C5 n5:271B5CBD-363D-11E5-9242-09173F13E4C5 n5:271B5CD2-363D-11E5-9242-09173F13E4C5 n5:271B5CBE-363D-11E5-9242-09173F13E4C5 n5:271B5CD3-363D-11E5-9242-09173F13E4C5 n5:271B5CBB-363D-11E5-9242-09173F13E4C5 n5:271B5CB0-363D-11E5-9242-09173F13E4C5 n5:271B5CD0-363D-11E5-9242-09173F13E4C5 n5:271B5CBC-363D-11E5-9242-09173F13E4C5 n5:271B5CD1-363D-11E5-9242-09173F13E4C5 n5:271B5CD4-363D-11E5-9242-09173F13E4C5 n5:271B5CD5-363D-11E5-9242-09173F13E4C5 n5:271B5CB2-363D-11E5-9242-09173F13E4C5 n5:271B5CB3-363D-11E5-9242-09173F13E4C5 n5:271B5CAE-363D-11E5-9242-09173F13E4C5 n5:271B5CAF-363D-11E5-9242-09173F13E4C5 n5:271B5CB6-363D-11E5-9242-09173F13E4C5 n5:271B5CB7-363D-11E5-9242-09173F13E4C5 n5:271B5CB4-363D-11E5-9242-09173F13E4C5 n5:271B5CB5-363D-11E5-9242-09173F13E4C5 n5:271B5CC2-363D-11E5-9242-09173F13E4C5 n5:271B5CC3-363D-11E5-9242-09173F13E4C5 n5:271B5CC0-363D-11E5-9242-09173F13E4C5 n5:271B5CC1-363D-11E5-9242-09173F13E4C5 n5:271B5CC6-363D-11E5-9242-09173F13E4C5 n5:271B5CC7-363D-11E5-9242-09173F13E4C5 n5:271B5CC4-363D-11E5-9242-09173F13E4C5 n5:271B5CC5-363D-11E5-9242-09173F13E4C5 n5:271B5CBF-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5D08-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5D0A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5D0B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5D0D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5D07-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5D06-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5D09-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5CF7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5D04-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5D05-363D-11E5-9242-09173F13E4C5